Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NALBUPHINE HYDROCHLORIDE vs TRANXENE SD
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mixed agonist-antagonist at mu-opioid receptor; full agonist at kappa-opioid receptor; weak antagonist at mu-opioid receptor.
Benzodiazepine that enhances GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal inhibition.
Moderate to severe pain,Supplement to balanced anesthesia,Preoperative and postoperative analgesia,Obstetrical analgesia during labor and delivery
Anxiety disorders,Short-term relief of anxiety symptoms,Acute alcohol withdrawal,Preoperative sedation (adjunctive),Partial seizures (adjunctive, off-label)
10-20 mg IM/IV/SC every 3-6 hours as needed; maximum single dose 20 mg, maximum daily dose 160 mg.
Oral: 11.25-22.5 mg once daily (sustained-release formulation).
Terminal elimination half-life is approximately 5 hours (range 3-6 hours) in adults; prolonged in hepatic impairment.
Terminal elimination half-life of nordazepam (active metabolite) is 30–100 hours (mean 50 hours); clorazepate itself has a short half-life (~2 hours) due to rapid conversion.
Hepatic via glucuronidation; primarily metabolized by UGT2B7; minor CYP450 involvement.
Hepatic via conjugation and oxidative metabolism; primary metabolite is desmethyldiazepam (active); CYP450 involvement (CYP3A4 and CYP2C19).
Primarily hepatic metabolism (CYP3A4 and glucuronidation); <5% excreted unchanged in urine; ~70% excreted as metabolites in urine, ~30% in feces.
Renal excretion of conjugated metabolites, with less than 1% unchanged drug; approximately 30% excreted in feces via biliary elimination.
Approximately 50% bound to plasma proteins, primarily albumin.
97–98% bound to albumin; nordazepam is highly protein-bound.
Approximately 2.6 L/kg (range 1.6-3.8 L/kg); indicates extensive tissue distribution.
0.9–1.4 L/kg for clorazepate; nordazepam Vd approximately 0.8–1.2 L/kg, indicating extensive tissue distribution.
Intramuscular and subcutaneous: approximately 80%; oral: low (extensive first-pass metabolism, <20% oral bioavailability).
Oral: 100% (prodrug fully converted); no parenteral formulation.
Cr Cl 30-50 m L/min: administer 75% of normal dose; Cr Cl 10-29 m L/min: administer 50% of normal dose; Cr Cl <10 m L/min: avoid use or use with extreme caution.
GFR <10 m L/min: Reduce dose by 25-50% and consider avoidance due to accumulation of active metabolites.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 25%; Child-Pugh Class C: reduce dose by 50% or avoid.
Child-Pugh Class B or C: Reduce dose by 50% or avoid use; monitor for excessive sedation.
0.1-0.2 mg/kg IV/IM/SC every 3-6 hours as needed; maximum single dose 20 mg.
Not recommended for patients <18 years due to lack of safety and efficacy data.
Initiate at 50% of adult dose (5-10 mg) and titrate cautiously due to increased sensitivity and risk of respiratory depression.
Reduce initial dose by 50% (e.g., 11.25 mg once daily or less), titrate slowly, and monitor for falls and cognitive impairment.
Risk of respiratory depression, abuse, misuse, and addiction; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death.
Respiratory depression; abuse potential; neonatal opioid withdrawal syndrome; adrenal insufficiency; severe hypotension; head injury and increased intracranial pressure; severe hepatic or renal impairment.
Risk of abuse, misuse, and addiction,Dependence and withdrawal reactions,CNS depressant effects (impairment of driving/operating machinery),Respiratory depression (especially with opioids),Glaucoma (narrow-angle) use cautiously,Suicidal ideation (pre-existing depression)
Hypersensitivity to nalbuphine or any component; significant respiratory depression; acute or severe bronchial asthma; paralytic ileus; suspected or known gastrointestinal obstruction; use of MAOIs within 14 days.
Hypersensitivity to clorazepate or other benzodiazepines,Acute narrow-angle glaucoma,Severe respiratory insufficiency,Myasthenia gravis,Concomitant use with opioids (in some contexts)
No specific food interactions. Avoid grapefruit juice as it may theoretically increase nalbuphine levels (CYP3A4 substrate, though major metabolism via glucuronidation). Maintain adequate hydration to prevent constipation.
Food may delay but does not significantly reduce absorption. Avoid grapefruit juice as it may inhibit CYP3A4, increasing nordazepam levels. Avoid alcohol completely.
Pregnancy Category C. No adequate well-controlled studies in pregnant women. Animal studies have shown no teratogenic effects but embryocidal effects at high doses. Use only if potential benefit justifies risk. In first trimester, avoid unless necessary. Second and third trimesters: risk of neonatal respiratory depression, withdrawal if chronic use. Near term: may prolong labor and cause neonatal respiratory depression.
First trimester: Increased risk of congenital malformations (oral clefts) reported with benzodiazepine use; data specifically for clorazepate limited but class effect assumed. Second/third trimester: Exposure may cause fetal CNS depression, hypotonia, respiratory depression, and withdrawal symptoms (e.g., jitteriness, hypertonia) in neonates.
Excreted in breast milk in small amounts; M/P ratio approximately 0.47-1.5. Limited data; caution recommended. Monitor infant for sedation and respiratory depression. Benefits of breastfeeding should outweigh risks.
Clorazepate is excreted into breast milk; M/P ratio approximately 0.2. Infant exposure likely low but may cause sedation. Use with caution; monitor infant for drowsiness and poor feeding. Consider alternative if high maternal doses or prolonged use.
No specific dose adjustment recommended for pregnancy, but pharmacokinetics may be altered due to increased volume of distribution and clearance. Dosing should be on an individual basis, titrated to effect. Use lowest effective dose and shortest duration. During labor, doses should be reduced due to potential for respiratory depression in neonate.
Increased volume of distribution and enhanced hepatic metabolism in pregnancy may lower serum clorazepate levels; consider dose increase if therapeutic effect inadequate. Avoid in first trimester if possible; use lowest effective dose in later trimesters. Taper gradually before delivery to minimize neonatal withdrawal.
Nalbuphine is a mixed agonist-antagonist opioid with ceiling effect on respiratory depression; less abuse liability than morphine. Useful for opioid-induced pruritus (e.g., with morphine) at low doses (0.1 mg/kg IV). May precipitate withdrawal in opioid-dependent patients. Avoid in opioid-tolerant patients on full agonists. Metabolized by liver; adjust dose in hepatic impairment. Not a controlled substance (US), but report to regulatory authorities as required.
TRANXENE SD (clorazepate dipotassium) is a long-acting benzodiazepine with a slow onset, making it less suitable for acute panic but effective for generalized anxiety. Its active metabolite, nordazepam, has a half-life of 40-100 hours, allowing once-daily dosing. Monitor for accumulation in elderly or hepatic impairment. Use with caution in patients with a history of substance abuse due to dependence risk.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,May cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how nalbuphine affects you.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, sedatives) as they increase risk of severe drowsiness, respiratory depression, coma, or death.,Do not stop suddenly after prolonged use; withdrawal symptoms may occur but are generally milder than with full agonists.,Report any signs of allergic reaction (rash, hives, swelling) or difficulty breathing immediately.,If you have been taking other opioids, inform your doctor to avoid withdrawal symptoms.,Store at room temperature away from heat, light, and moisture; keep out of reach of children.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not stop abruptly; reduce dose gradually to avoid withdrawal symptoms (e.g., anxiety, insomnia, seizures).,Avoid alcohol and other CNS depressants (e.g., opioids, sedatives) as they increase sedation and respiratory depression risk.,May cause drowsiness or dizziness; avoid driving or operating heavy machinery until you know how the drug affects you.,Report any unusual changes in mood, thoughts, or behavior (e.g., depression, suicidal thoughts).,Use effective contraception if of childbearing potential due to fetal harm risk; notify prescriber if pregnant or breastfeeding.
"The combination of trifluoperazine, a phenothiazine antipsychotic, with nalbuphine, a mixed opioid agonist-antagonist, can lead to additive central nervous system (CNS) depression, including increased sedation, respiratory depression, and hypotension. Trifluoperazine may enhance the depressant effects of nalbuphine on the brainstem respiratory centers and vasomotor centers. Clinically, this interaction may result in excessive sedation, respiratory compromise, and orthostatic hypotension, particularly in elderly or debilitated patients."
"Combined use of nalbuphine, a mixed opioid agonist-antagonist, with entacapone, a catechol-O-methyltransferase (COMT) inhibitor, may increase the risk of opioid-related adverse effects, including respiratory depression and sedation, due to additive central nervous system depression. Entacapone can also inhibit the metabolism of catecholamines, potentially exacerbating opioid-induced constipation and urinary retention. Clinically, patients may experience enhanced sedation or respiratory compromise, particularly in elderly or debilitated populations."
"Concomitant use of clozapine and nalbuphine may potentiate central nervous system (CNS) depression, leading to additive sedative and respiratory depressant effects. Both drugs act on the CNS via distinct mechanisms but converge on common pathways, increasing the risk of hypotension, bradycardia, and profound sedation. Clinically, patients may experience excessive drowsiness, confusion, or respiratory compromise, particularly in those with pre-existing comorbidities or concurrent use of other CNS depressants."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NALBUPHINE HYDROCHLORIDE vs TRANXENE SD, answered by our medical review team.
NALBUPHINE HYDROCHLORIDE is a Opioid Agonist-Antagonist that works by Mixed agonist-antagonist at mu-opioid receptor; full agonist at kappa-opioid receptor; weak antagonist at mu-opioid receptor.. TRANXENE SD is a Benzodiazepine Anxiolytic that works by Benzodiazepine that enhances GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NALBUPHINE HYDROCHLORIDE and TRANXENE SD depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NALBUPHINE HYDROCHLORIDE is: 10-20 mg IM/IV/SC every 3-6 hours as needed; maximum single dose 20 mg, maximum daily dose 160 mg.. The standard adult dose of TRANXENE SD is: Oral: 11.25-22.5 mg once daily (sustained-release formulation).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NALBUPHINE HYDROCHLORIDE and TRANXENE SD in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NALBUPHINE HYDROCHLORIDE is classified as Category A/B. Pregnancy Category C. No adequate well-controlled studies in pregnant women. Animal studies have shown no teratogenic effects but embryocidal effects at high doses. Use only if pot. TRANXENE SD is classified as Category C. First trimester: Increased risk of congenital malformations (oral clefts) reported with benzodiazepine use; data specifically for clorazepate limited but class effect assumed. Seco. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.